Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Currier, Judith S."'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Evering, Teresa H, Chew, Kara W, Giganti, Mark J, Moser, Carlee, Pinilla, Mauricio, Wohl, David Alain, Currier, Judith S, Eron, Joseph J, Javan, Arzhang Cyrus, Bender Ignacio, Rachel, Margolis, David, Zhu, Qing, Ma, Ji, Zhong, Lijie, Yan, Li, D'Andrea Nores, Ulises, Hoover, Keila, Mocherla, Bharat, Choudhary, Manish C, Deo, Rinki, Ritz, Justin, Fischer, William A, Fletcher, Courtney V, Li, Jonathan Z, Hughes, Michael D, Smith, Davey, Daar, Eric S, ACTIV-2/A5401 Study Team
Publikováno v:
Annals of internal medicine, vol 176, iss 5
BackgroundDevelopment of safe and effective SARS-CoV-2 therapeutics is a high priority. Amubarvimab and romlusevimab are noncompeting anti-SARS-CoV-2 monoclonal antibodies with an extended half-life.ObjectiveTo assess the safety and efficacy of amuba
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::c79d1051380407ddaf9d917aa698652b
https://escholarship.org/uc/item/1pr201tq
https://escholarship.org/uc/item/1pr201tq
Autor:
Choudhary, Manish C, Chew, Kara W, Deo, Rinki, Flynn, James P, Regan, James, Crain, Charles R, Moser, Carlee, Hughes, Michael D, Ritz, Justin, Ribeiro, Ruy M, Ke, Ruian, Dragavon, Joan A, Javan, Arzhang Cyrus, Nirula, Ajay, Klekotka, Paul, Greninger, Alexander L, Fletcher, Courtney V, Daar, Eric S, Wohl, David A, Eron, Joseph J, Currier, Judith S, Parikh, Urvi M, Sieg, Scott F, Perelson, Alan S, Coombs, Robert W, Smith, Davey M, Li, Jonathan Z, ACTIV-2/A5401 Study Team
Publikováno v:
Nature microbiology, vol 7, iss 11
Nat Microbiol
Nat Microbiol
SARS-CoV-2 mutations that cause resistance to monoclonal antibody (mAb) therapy have been reported. However, it remains unclear whether in vivo emergence of SARS-CoV-2 resistance mutations alters viral replication dynamics or therapeutic efficacy in
Autor:
Ramirez, Sydney I, Grifoni, Alba, Weiskopf, Daniela, Parikh, Urvi M, Heaps, Amy, Faraji, Farhoud, Sieg, Scott F, Ritz, Justin, Moser, Carlee, Eron, Joseph J, Currier, Judith S, Klekotka, Paul, Sette, Alessandro, Wohl, David A, Daar, Eric S, Hughes, Michael D, Chew, Kara W, Smith, Davey M, Crotty, Shane, Accelerating COVID-19 Therapeutic Interventions and Vaccines–2/A5401 (ACTIV-2/A5401) Study Team
Publikováno v:
JCI insight, vol 7, iss 24
Despite the widespread use of SARS-CoV-2-specific monoclonal antibody (mAb) therapy for the treatment of acute COVID-19, the impact of this therapy on the development of SARS-CoV-2-specific T cell responses has been unknown, resulting in uncertainty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::b28ef16a6d0cb44f490d4a1bad157888
https://escholarship.org/uc/item/2cj3m23p
https://escholarship.org/uc/item/2cj3m23p
Autor:
Bender Ignacio, Rachel A, Wohl, David A, Arends, Rosalin, Pilla Reddy, Venkatesh, Mu, Ying, Javan, Arzhang Cyrus, Hughes, Michael D, Eron, Joseph J, Currier, Judith S, Smith, Davey, Chew, Kara W, Gibbs, Michael, Fletcher, Courtney V
Publikováno v:
Clinical pharmacology and therapeutics, vol 112, iss 6
AZD7442 (Evusheld) is a combination of two human anti-severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs), tixagevimab (AZD8895) and cilgavimab (AZD1061). Route of administration is an important consideration to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::c4b75d262baeea78cfd16043769fd496
https://escholarship.org/uc/item/0x83039c
https://escholarship.org/uc/item/0x83039c
Autor:
Moser, Carlee, Li, Jonathan Z, Eron, Joseph J, Aga, Evgenia, Daar, Eric S, Wohl, David A, Coombs, Robert W, Javan, Arzhang Cyrus, Bender Ignacio, Rachel A, Jagannathan, Prasanna, Ritz, Justin, Sieg, Scott F, Parikh, Urvi M, Hughes, Michael D, Currier, Judith S, Smith, Davey M, Chew, Kara W, ACTIV-2/A5401 Study Team
Publikováno v:
Open forum infectious diseases, vol 9, iss 11
BackgroundIdentifying characteristics associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA shedding may be useful to understand viral compartmentalization, disease pathogenesis, and risks for viral transmission.MethodsPart
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::e8be2edf1503432175a8dfa26234e054
https://escholarship.org/uc/item/1j29k6hg
https://escholarship.org/uc/item/1j29k6hg
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Friedland, Anne, Hernandez, Adrian F, Anstrom, Kevin J, Chen-Lim, Mei Lin, Cohen, Lauren W, Currier, Judith S, Forrest, Christopher B, Fraser, Ryan, Fraulo, Elizabeth, George, Anoop, Handberg, Eileen, Jackman, Jennifer, Koellhoffer, Jayne, Lawrence, Daryl, Leverty, Renee, McAdams, Patty, McCourt, Brian, Mickley, Brenda, Naqvi, Syed Hasan, O'Brien, Emily C, Olson, Rachel, Prater, Clyde, Rothman, Russell L, Shenkman, Elizabeth, Shostak, Jack, Turner, Kisha Batey, Webb, Laura, Woods, Chris, Naggie, Susanna, HERO Research Program
BackgroundThe SARS CoV-2 virus has caused one of the deadliest pandemics in recent history, resulting in over 170 million deaths and global economic disruption. There remains an urgent need for clinical trials to test therapies for treatment and prev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::eb127050e86b1294079b4f425fd0bbb9
https://escholarship.org/uc/item/21q1d33f
https://escholarship.org/uc/item/21q1d33f
Autor:
El Kamari, Vanessa, Rodriguez, Katherine, Moser, Carlee, Currier, Judith S, Kelesidis, Theodoros, Stein, James H, Brown, Todd T, Howell, Scott K, Beisswenger, Paul J, McComsey, Grace A
Publikováno v:
Open forum infectious diseases, vol 8, iss 10
BackgroundDespite advances in antiretroviral therapy (ART), people living with human immunodeficiency virus (HIV) continue to be at increased risk of cardiometabolic complications compared to HIV-uninfected individuals. Advanced glycation end product
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::5e5e1c19cddcebe350184e8dc19771ab
https://escholarship.org/uc/item/7mt1v78t
https://escholarship.org/uc/item/7mt1v78t
Autor:
LaVange, Lisa, Adam, Stacey J, Currier, Judith S, Higgs, Elizabeth S, Reineck, Lora A, Hughes, Eric A, Read, Sarah W, ACTIV Therapeutics-Clinical Working Group
Publikováno v:
Annals of internal medicine, vol 174, iss 9
Working in an unprecedented time frame, the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) public-private partnership developed and launched 9 master protocols between 14 April 2020 and 31 May 2021 to allow for the coordinated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______325::78992259da5af20da183bcdaac004184
https://escholarship.org/uc/item/69v0p03f
https://escholarship.org/uc/item/69v0p03f